Rheumatology revenue depends on infused and injected biologic drugs and on joint injections. Each drug needs the right code and units, waste must be reported as the payer requires, and most biologics need authorization, often tied to earlier treatments and lab monitoring.
Common billing challenges in Rheumatology
- Infusion drug billing, with drug codes, units and administration codes that match what was given
- Drug waste reporting for single-dose containers
- Prior authorization for biologics, with documentation of diagnosis, earlier treatments and monitoring
- Joint injections, billed by joint size and with or without imaging guidance, as the codes describe
- Buy-and-bill versus specialty pharmacy supply, and how each is billed
- Same-day visit and procedure or infusion, which may need modifier 25
How we support Rheumatology practices
- Eligibility and Prior Authorization: Benefit checks and approvals before care
- Medical Coding: Certified coding for visits and procedures
- Denial Management and A/R Recovery: Appeals and aged-claim follow-up
- Medical Billing and Coding Audit: Find errors, underpayments and compliance gaps
Not every practice needs every service. We can start with the area causing the most pain and add more later.
Helpful guides
- Prior authorization guide
- How to reduce claim denials
- Clean claim checklist
- Claim denial codes explained
- Modifiers 25 and 59
Frequently asked questions
How are infusion drugs billed?
The drug is billed with its code and units, and the administration with the right infusion or injection code. Many payers also want NDCs and waste reported.
Do biologics need prior authorization?
Almost always, with criteria such as diagnosis, prior therapies and lab results. We track approvals and renewal dates.
What is the difference between buy-and-bill and specialty pharmacy?
In buy-and-bill the practice buys and bills for the drug. With specialty pharmacy, the pharmacy supplies the drug and the practice bills only for administration.
